Sandford Sommer joins Vernalis as President & Chief Operating Officer

Prior to joining the UK firm Sommer spent 24 years at AstraZeneca

Vernalis has hired Sandford (Sandy) Sommer as President & Chief Operating Officer.

Prior to joining the UK-based drug developer, Sommer spent 24 years at AstraZeneca, holding increasingly senior roles in sales and marketing, and general management. Most recently he was President of AstraZeneca´s Colombia operations. Prior to this, he held a variety of leadership roles, including Global Vice President of CNS, Infection and Flu Vaccines. In the US he was Executive Director for the Seroquel franchise. He has extensive experience building brands and has been instrumental in the success of Seroquel, Nexium, and Symbicort.

Sommer has been on the Board of the UK Colombia Trade organisation for the last two years. He began his career with sales and management positions at Astra/Merck.

You may also like

Research & Development

Three milestones in Servier and Vernalis oncology drug discovery collaboration

Two research milestones and one clinical milestone, triggering a total payment of €2m to Vernalis
Research & Development

Servier and Vernalis announce three milestones in their oncology drug discovery collaboration

Two research milestones and one clinical milestone reached, triggering a total payment of €2 million to Vernalis
Research & Development

Vernalis and Servier enter drug discovery collaboration

Vernalis and Servier will enter into a new two-year oncology drug discovery collaboration on an undisclosed target
Regulatory

FDA accepts CCP-08 NDA for full review

PDUFA date of 4 August 2017
Research & Development

Pharmaceutical industry rewarded in Queen\'s Awards for Enterprise 2014

Four companies honoured for International Trade and two for Innovation
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Subscribe now